A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 6, 2020

Primary Completion Date

November 14, 2021

Study Completion Date

December 13, 2021

Conditions
Panic Disorder
Interventions
DRUG

CVL-865 High dose

High dose CVL-865: Will be administered as 5mg BID for 2 days followed by 12.5mg BID for another 2 days during the Titration Phase. 25mg will be administered during the Maintenance Phase (3 days of BID and morning dose only on the 4th day)

DRUG

Alprazolam 1mg XR

Alprazolam 1mg XR will be administered for 8 days BID (morning dose only on 8th day)

DRUG

Placebo

Placebo, oral tablet/capsule will be administered for 8 days BID (morning dose only on 8th day)

DRUG

CVL-865 low dose

Low dose CVL-865, oral tablets. Will be administered as 2.5mg BID for 2 days followed by 5mg BID for another 2 days during the Titration Phase. 7.5mg BID will be administered during the Maintenance Phase (3 days of BID and morning dose only on 4th day)

Trial Locations (1)

2333 CL

Centre for Human Drug Research, Leiden

Sponsors
All Listed Sponsors
lead

Cerevel Therapeutics, LLC

INDUSTRY

NCT04592536 - A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects | Biotech Hunter | Biotech Hunter